Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria

FEMS Microbiology Reviews

Volumn 36, Issue 2, 2012, Pages 340-363

  Nikaido, Hiroshi ^a   Pagès, Jean Marie ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Aix Marseille University   (France)

Author keywords

Antibiotic resistance; Bacterial efflux pump; MDR bacteria; Outer membrane permeability; RND family drug transporters; Structure function relationship

Indexed keywords

ACRB PROTEIN; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CARRIER PROTEIN; CEFOXITIN; CEPHALOSPORIN; CHLORAMPHENICOL; CLOXACILLIN; EFFLUX PUMP INHIBITOR; ERYTHROMYCIN; MACROLIDE; MEXB PROTEIN; NOVOBIOCIN; OUTER MEMBRANE PROTEIN; PENICILLIN G; PORIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING AFFINITY; CELL LEVEL; DOWN REGULATION; DRUG BINDING SITE; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; GENE OVEREXPRESSION; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 84856729230     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2011.00290.x     Document Type: Review

References (199)

1. Aathithan S & French GL (2011) Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae. Eur J Clin Microbiol J Infect Dis 30: 745-752.
2. Alekshun MN & Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell128: 1037-1050.
3. Amábile-Cuevas CF, Arredondo-García JL, Cruz A & Rosas I (2010) Fluoroquinolone resistance in clinical and environmental isolates of Escherichia coli in Mexico City. J Appl Microbiol108: 158-162.
4. Amaral L, Pagès JM & Fanning S (2011) Efflux pumps of Gram-negative bacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors and phenothaizines. Adv EnzymolRAMB 77: 61-108.
5. Amicosante G, Oratore A, Franceschini N, Maccarrone M, Strom R, Galleni M & Frere JM (1988) Citrobacter diversus ULA-27 β-lactamases. Improved purification and general properties. Biochem J254: 885-890.
6. Bakken JS, Sanders CC & Thomson KS (1987) Selective ceftazidime resistance in Escherichia coli: association with changes in outer membrane protein. J Infect Dis 155: 1220-1225.
7. Bal AM, Kumar A & Gould IM (2010) Antibiotic heterogeneity: from concept to practice. Ann NY Acad Sci 1213: 81-91.
8. Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, He W, Queenan AM & Bush K (2009) Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Ch53: 2785-2790.
9. Beaudoin T, Aaron SD, Giesbrecht-Lewis T, Vandemheen K & Mah TF (2010) Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada. Can J Microbiol56: 548-557.
10. Becnel Boyd L, Maynard MJ, Morgan-Linnell SK, Horton LB, Sucgang R, Hamill RJ, Jimenez JR, Versalovic J, Steffen D & Zechiedrich L (2009) Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Ch53: 229-234.
11. Benz R, Schmid A & Vos-Scheperkeuter GH (1987) Mechanism of sugar transport through the sugar-specific LamB channel of Escherichia coli outer membrane. J Membrane Biol100: 21-29.
12. Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM & Nicolas-Chanoine MH (2010) Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob Agents Ch54: 4373-4378.
13. Blot S, Depuydt P, Vandewoude K & De Bacquer D (2007) Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis20: 391-396.
14. Bohnert JA & Kern WV (2005) Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Ch49: 849-852.
15. Bohnert JA, Schuster S, Seeger MA, Fahnrich E, Pos KM & Kern WV (2008) Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB. J Bacteriol190: 8225-8229.
16. Bornet C, Davin-Regli A, Bosi C, Pagès JM & Bollet C (2000) Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol38: 1048-1052.
17. Bornet C, Chollet R, Malléa M, Chevalier J, Davin-Regli A, Pagès JM & Bollet C (2003) Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem Bioph Res Co301: 985-990.
18. Boutoille D, Corvec S, Caroff N, Giraudeau C, Espaze E, Caillon J, Plésiat P & Raynaud A (2004) Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing β-lactam resistance. FEMS Microbiol Lett230: 143-146.
19. Bratu S, Landman D, George A, Salvani J & Quale J (2009) Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City. J Antimicrob Chemoth64: 278-283.
20. Bush K & Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Ch54: 969-976.
21. Charrel RN, Pagès JM, De Micco P & Mallea M (1996) Prevalence of outer membrane porin alteration in β-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob Agents Ch40: 2854-2858.
22. Chau SL, Chu YW & Houang ET (2004) Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob Agents Ch48: 4054-4055.
23. Chevalier J, Pagès JM & Mallea M (1999) In vivo modification of porin activity conferring antibiotic resistance to Enterobacter aerogenes. Biochem Bioph Res Co266: 248-251.
24. Chevalier J, Bredin J, Mahamoud A, Malléa M, Barbe J & Pagès JM (2004) Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Ch48: 1043-1046.
25. Chevalier J, Mulfinger C, Garnotel E, Nicolas P, Davin-Régli A & Pagès JM (2008) Identification and evolution of drug efflux pump in clinical Enterobacter aerogenes strains isolated in 1995 and 2003. PLoS One3: e3203.
26. Chevalier J, Mahamoud A, Baitiche M, Adam E, Viveiros M, Smarandache A, Militaru A, Pascu ML, Amaral L & Pagès JM (2010) Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Ag36: 164-168.
27. Chiu CH, Lee HY, Tseng LY, Chen CL, Chia JH, Su LH & Liu SY (2010) Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan. Int J Antimicrob Ag35: 382-386.
28. Cho D, Blais J, Tangen K, Ford C, Lee A, Lomovskaya O, Chamberland S & Miller GH (1999) Prevalence of efflux pumps among clinical isolates of fluoroquinolone-resistant Pseudomonas aeruginosa. Abstracts, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: September 26-29; 39: 327(abstract no. 1267).
29. Chopra I, Schofield C, Everett Met al. (2008) Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 8: 133-139.
30. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK & Yu VL (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115: 585-590.
31. Chu YW, Chau SL & Houang ET (2006) Presence of active efflux systems AdeABC, AdeDE and AdeXYZ in different Acinetobacter genomic DNA groups. J Med Microbiol55: 477-478.
32. Coyne S, Rosenfeld N, Lambert T, Courvalin P & Périchon B (2010) Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents54: 4389-4393.
33. Coyne S, Courvalin P & Périchon B (2011) Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Che55: 947-53.
34. Damier-Piolle L, Magnet S, Brémont S, Lambert T & Courvalin P (2008) AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumanii. Antimicrob Agents Ch52: 557-562.
35. Danelon C, Nestorovich EM, Winterhalter M, Ceccarelli M & Bezrukov SM (2006) Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophys J90: 1617-1627.
36. Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, Garnotel E, Molitor A & Pagès JM (2008) Membrane permeability and regulation of drug 'influx and efflux' in enterobacterial pathogens. Curr Drug Targets9: 750-759.
37. Dé E, Basle A, Jaquinod M, Saint N, Mallea M, Molle G & Pagès JM (2001) A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol Microbiol41: 189-198.
38. Dhamdhere G & Zgurskaya HI (2010) Metabolic shutdown in Escherichia coli cells lacking the outer membrane channel TolC. Mol Microbiol77: 743-754.
39. Drew D, Klepsch MM, Newstead S, Flaig R, De Gier JW, Iwata S & Beis K (2008) The structure of the efflux pump AcrB in complex with bile acid. Mol Membr Biol25: 677-682.
40. Dunham SA, McPherson CJ & Miller AA (2010) The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol29: 279-288.
41. Eicher T, Brandstätter L & Pos KM (2009) Structural and functional aspects of the multidrug efflux pump AcrB. Biol Chem390: 693-699.
42. Elkins CA & Mullis LB (2006) Mammalian steroid hormones are substrates for the major RND- and MFS-type tripartite multidrug efflux pumps of Escherichia coli. J Bacteriol188: 1191-1195.
43. Elkins CA & Nikaido H (2002) Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J Bacteriol184: 6490-6498.
44. Falagas ME & Bliziotis IA (2007) Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Ag 29: 630-636.
45. Fange D, Nilsson K, Tenson T & Ehrenberg M (2009) Drug efflux pump deficiency and drug target resistance masking in growing bacteria. P Natl Acad Sci USA106: 8215-8220.
46. Fernández L, Breidenstein EB & Hancock RE (2011) Creeping baselines and adaptive resistance to antibiotics. Drug Resist Update14: 1-21.
47. Fischbach MA & Walsh CT (2009) Antibiotics for emerging pathogens. Science325: 1089-1093.
48. Fishbain J & Peleg AY (2010) Treatment of Acinetobacter infections. Clin Infect Dis51: 79-84.
49. Fluman N & Bibi E (2009) Bacterial multidrug transport through the lens of the major facilitator superfamily. Biochim Biophys Acta1794: 738-747.
50. Gandhi TN, DePestel DD, Collins CD, Nagel J & Washer LL (2010) Managing antimicrobial resistance in intensive care units. Crit Care Med38(suppl 8): S315-S323.
51. Ghisalberti D, Mahamoud A, Chevalier J, Baitiche M, Martino M, Pagès JM & Barbe J (2006) Chloroquinolines block antibiotic efflux pumps in antibiotic-resistant Enterobacter aerogenes isolates. Int J Antimicrob Ag27: 565-569.
52. Giamarellou H & Poulakou G (2009) Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69: 1879-1901.
53. Glatz K, Tóth A & Pászti J (2010) The cyclohexane tolerance and Phe-Arg-β-naphtylamide susceptibility of multidrug-resistant Enterobacter cloacae clinical isolates, and the predominance of one PFGE clone in Hungary. Clin Microbiol Infec DOI: DOI: 10.1111/j.1469-0691.2010.03408.x Epub ahead of print.
54. Gwynn MN, Portnoy A, Rittenhouse SF & Payne DJ (2010) Challenges of antibacterial discovery revisited. Ann NY Acad Sci1213: 5-19.
55. Haeggman S, Löfdahl S, Paauw A, Verhoef J & Brisse S (2004) Diversity and evolution of the class A chromosomal beta-lactamase gene in. Antimicrob Agents Che48: 2400-2408.
56. Hajjar E, Bessonov A, Molitor A, Kumar A, Mahendran KR, Winterhalter M, Pagès JM, Ruggerone P & Ceccarelli M (2010) Toward screening for antibiotics with enhanced permeation properties through bacterial porins. Biochemistry49: 6928-6935.
57. Hanberger H, Nilsson LE, Kihlstrom E & Maller R (1990) Postantibiotic effect of β-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. Antimicrob Agents Ch34: 102-106.
58. Hancock RE (1981) Aminoglycoside uptake and mode of action-with special reference to streptomycin and gentamicin. II. Effects of aminoglycosides on cells. J Antimicrob Chemoth8: 429-445.
59. Harder KJ, Nikaido H & Matsuhashi M (1981) Mutants of Escherichia coli that are resistant to certain β-lactam compounds lack the OmpF porin. Antimicrob Agents Ch20: 549-552.
60. Hasdemir UO, Chevalier J, Nordmann P & Pagès JM (2004) Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol42: 2701-2706.
61. Hegstad K, Langsrud S, Lunestad BT, Scheie AA, Sunde M & Yazdankhah SP (2011) Does the wide use of quaternary ammonium compounds enhance the selection and spread of antimicrobial resistance and thus threaten our health?Microb Drug Resist16: 91-104.
62. Hirsch EB & Tam VH (2010) Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res10: 441-451.
63. Hocquet D, Nordmann P, El Garch F, Cabanne L & Plésiat P (2006) Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Ch50: 1347-1351.
64. Hocquet D, Roussel-Delvallez M, Cavallo JD & Plésiat P (2007) MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Ch51: 1582-1583.
65. Hocquet D, Muller A, Blanc K, Plésiat P, Talon D, Monnet DL & Bertrand X (2008) Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Ch52: 1173-1175.
66. Hornsey M, Ellington MJ, Doumith M, Scott G, Livermore DM & Woodford N (2010) Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. Int J Antimicrob Ag35: 478-481.
67. Houang ET, Chu YW, Chu KY, Ng KC, Leung CM & Cheng AF (2003) Significance of genomic DNA group delineation in comparative studies of antimicrobial susceptibility of Acinetobacter spp. Antimicrob Agents Ch47: 1472-1475.
68. Husain F & Nikaido H (2010) Substrate path in the AcrB multidrug efflux pump of Escherichia coli. Mol Microbiol78: 320-330.
69. Islam S, Oh H, Jalal S, Karpati F, Ciofu O, Høiby N & Wretlind B (2009) Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infec15: 60-66.
70. James CE, Mahendran KR, Molitor A, Bolla JM, Bessonov AN, Winterhalter M & Pagès JM (2009) How β-lactam antibiotics enter bacteria: a dialogue with the porins. PLoS One 4: e5453.
71. Jones D (2010a) News and analysis: the antibacterial lead discovery challenge. Nat Rev Drug Discov 9: 751-752.
72. Jones RN (2010b) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis51(suppl 1): S81-S87.
73. Källman O, Motakefi A, Wretlind B, Kalin M, Olsson-Liljequist B & Giske CG (2008) Cefuroxime non-susceptibility in multidrug-resistant Klebsiella pneumoniae overexpressing ramA and acrA and expressing ompK35 at reduced levels. J Antimicrob Chemoth62: 986-990.
74. Källman O, Giske CG, Samuelsen Ø, Wretlind B, Kalin M & Olsson-Liljequist B (2009) Interplay of efflux, impermeability, and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli. Microb Drug Resist15: 91-95.
75. Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H & Bohnert JA (2006) Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemoth57: 339-343.
76. Kerr KG & Snelling AM (2009) Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 73: 338-344.
77. Kim JY, Kim SH, Jeon SM, Park MS, Rhie HG & Lee BK (2008) Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea. Clin Microbiol Infec14: 760-765.
78. Kiser TH, Obritsch MD, Jung R, MacLaren R & Fish DN (2010) Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy30: 632-638.
79. Komp Lindgren P, Karlsson A & Hughes D (2003) Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Ch47: 3222-3232.
80. Kreusch A, Neubuser A, Schiltz E, Weckesser J & Schulz GE (1994) Structure of the membrane channel porin from Rhodopseudomonas blastica at 2.0Å resolution. Protein Sci3: 58-63.
81. Landman D, Bratu S & Quale J (2009) Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol58: 1303-1308.
82. Lautenbach E, Fishman NO, Metlay JP, Mao X, Bilker WB, Tolomeo P & Nachamkin I (2006) Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 194: 79-85.
83. Lautenbach E, Metlay JP, Mao X, Han X, Fishman NO, Bilker WB, Tolomeo P, Wheeler M & Nachamkin I (2010) The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis51: 280-285.
84. Lavigne JP, Sotto A, Nicolas-Chanoine MH, Bouziges N, Bourg G, Davin-Regli A & Pagés JM (2011) Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. Clin Microbiol Infect in press.
85. Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okamura R, Ishida H & Lomovskaya O (2000) Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol182: 3142-3150.
86. Levy SB (2002) Active efflux, a common mechanism for biocide and antibiotic resistance. Symp Ser Soc Appl Microbiol31: 65S-71S.
87. Li XZ & Nikaido H (2004) Efflux-mediated drug resistance in bacteria. Drugs64: 159-204.
88. Li XZ & Nikaido H (2009) Efflux-mediated drug resistance in bacteria: an update. Drugs 69: 1555-1623.
89. Li XZ, Livermore DM & Nikaido H (1994) Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Ch 38: 1732-1741.
90. Lim SP & Nikaido H (2010) Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. Antimicrob Agents Ch54: 1800-1806.
91. Lister PD, Wolter DJ & Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22: 582-610.
92. Lomovskaya O & Bostian KA (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem Pharmacol71: 910-918.
93. Lomovskaya O, Warren MS, Lee Aet al. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Ch 45: 105-116.
94. Lovmar M, Nilsson K, Lukk E, Vimberg V, Tenson T & Ehrenberg M (2009) Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency. EMBO J28: 736-744.
95. Lunn AD, Fàbrega A, Sánchez-Céspedes J & Vila J (2010) Prevalence of mechanisms decreasing quinolone-susceptibility among Salmonella spp. clinical isolates. Int Microbiol13: 15-20.
96. Ma D, Alberti M, Lynch C, Nikaido H & Hearst JE (1996) The local repressor AcrR plays a modulating role in the regulation of AcrAB genes of Escherichia coli by global stress signals. Mol Microbiol19: 101-112.
97. Magnet S, Courvalin P & Lambert T (2001) Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Ch45: 3375-3380.
98. Mahamoud A, Chevalier J, Baitiche M, Adam E & Pagès JM (2011) An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology157: 566-571.
99. Malléa M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, Bollet C & Pagès JM (1998) Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 144: 3003-3009.
100. Malléa M, Mahamoud A, Chevalier J, Alibert-Franco S, Brouant P, Barbe J & Pagès JM (2003) Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates. Biochem J376: 801-805.
101. Mamelli L, Prouzet-Mauléon V, Pagès JM, Mégraud F & Bolla JM (2005) Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. J Antimicrob Chemoth 56: 491-497.
102. Mao W, Warren MS, Black DS, Satou T, Murata T, Nishino T, Gotoh N & Lomovskaya O (2002) On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol Microbiol 46: 889-901.
103. Maragakis LL (2010) Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med38(suppl 8): S345-S351.
104. Martin YC, Jones PH, Perun TJ, Grudy WE, Bell S, Bower RR & Shipkowitz NL (1972) Chemical modification of erythromycin antibiotics. 4. Structure-activity relations of erythromycin esters. J Med Chem15: 635-638.
105. Martinez JL, Sánchez MB, Martínez-Solano L, Hernandez A, Garmendia L, Fajardo A & Alvarez-Ortega C (2009) Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol Rev33: 430-449.
106. Mazzariol A, Cornaglia G & Nikaido H (2000) Contributions of the AmpC β-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to β-lactams. Antimicrob Agents Ch44: 1387-1390.
107. McMurry LM, Cullinane JC & Levy SB (1982) Transport of the lipophilic analog minocycline differs from that of tetracycline in susceptible and resistant Escherichia coli strains. Antimicrob Agents Ch22: 791-799.
108. Medeiros AA, O'Brien TF, Rosenberg EY & Nikaido H (1987) Loss of OmpC porin in a strain of Salmonella typhimurium causes increased resistance to cephalosporins during therapy. J Infect Dis156: 751-757.
109. Misra R & Benson SA (1988) Isolation and characterization of OmpC porin mutants with altered pore properties. J Bacteriol170: 528-533.
110. Morgan-Linnell SK, Becnel Boyd L, Steffen D & Zechiedrich L (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Ch53: 235-241.
111. Murakami S (2008) Multidrug efflux transporter, AcrB - the pumping mechanism. Curr Opin Struc Biol18: 459-465.
112. Murakami S, Nakashima R, Yamashita E & Yamaguchi A (2002) Crystal structure of bacterial multidrug efflux transporter AcrB. Nature419: 587-593.
113. Murakami S, Nakashima R, Yamashita E, Matsumoto T & Yamaguchi A (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature443: 173-179.
114. Nagano K & Nikaido H (2009) Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli. P Natl Acad Sci USA106: 5854-5858.
115. Nakae R & Nakae T (1982) Diffusion of aminoglycoside antibiotics across the outer membrane of Escherichia coli. Antimicrob Agents Ch22: 554-559.
116. Nakayama K, Ishida Y, Ohtsuka Met al. (2003) MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg Med Chem Lett 13: 4201-4204.
117. Nestorovich EM, Danelon C, Winterhalter M & Bezrukov SM (2002) Designed to penetrate: time-resolved interaction of single antibiotic molecules with bacterial pores. P Natl Acad Sci USA 99: 9789-9794.
118. Nikaido H (1996) Multidrug efflux pumps of gram-negative bacteria. J Bacteriol178: 5853-5859.
119. Nikaido H (1998) The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?Drug Resist Update1: 93-98.
120. Nikaido H (2001) Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol 12: 215-223.
121. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol R67: 593-656.
122. Nikaido H (2009) Multidrug resistance in bacteria. Annu Rev Biochem78: 119-146.
123. Nikaido H & Normark S (1987) Sensitivity of Escherichia coli to various β-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: a quantitative predictive treatment. Mol Microbiol 1: 29-36.
124. Nikaido H & Rosenberg EY (1983) Porin channels in Escherichia coli: studies with liposomes reconstituted from purified proteins. J Bacteriol 153: 241-252.
125. Nikaido H & Takatsuka Y (2009) Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta1794: 769-781.
126. Nikaido H & Vaara M (1985) Molecular basis of bacterial outer membrane permeability. Microbiol Rev49: 1-32.
127. Nikaido H, Rosenberg EY & Foulds J (1983) Porin channels in Escherichia coli: studies with β-lactams in intact cells. J Bacteriol 153: 232-240.
128. Nikaido H, Liu W & Rosenberg EY (1990) Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Ch34: 337-342.
129. Nikaido H, Basina M, Nguyen V & Rosenberg EY (1998) Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those β-lactam antibiotics containing lipophilic side-chains. J Bacteriol180: 4686-4692.
130. Okusu H, Ma D & Nikaido H (1996) AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (mar) mutants. J Bacteriol178: 306-308.
131. O'Regan E, Quinn T, Pagès JM, McCusker M, Piddock L & Fanning S (2009) Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators. Antimicrob Agents Ch 53: 1080-1087.
132. Pachón J & Vila J (2009) Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Investig D10: 150-156.
133. Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA & Albertí S (2010) Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. Antimicrob Agents Ch54: 177-183.
134. Pagès JM & Amaral L (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 1794: 826-833.
135. Pagès JM, James CE & Winterhalter M (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6: 893-903.
136. Pagès JM, Lavigne JP, Leflon-Guibout V, Marcon E, Bert F, Noussair L & Nicolas-Chanoine MH (2009) Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates. PLoS One4: e4817.
137. Pagès JM, Alibert-Franco S, Mahamoud A, Bolla JM, Davin-Regli A, Chevalier J & Garnotel E (2010) Efflux pumps of gram-negative bacteria, a new target for new molecules. Curr Top Med Chem8: 1848-1857.
138. Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA, Oliver A, Pujol M & Ariza J (2009) Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 beta-lactamase. J Clin Microbiol47: 2381-2387.
139. Pérez A, Canle D, Latasa Cet al. (2007) Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. Antimicrob Agents Ch51: 3247-3253.
140. Pérez-Boto D, López-Portolés JA, Simón C, Valdezate S & Echeita MA (2010) Study of the molecular mechanisms involved in high-level macrolide resistance of Spanish Campylobacter jejuni and Campylobacter coli strains. J Antimicrob Chemoth65: 2083-2088.
141. Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev19: 382-402.
142. Piddock LJ (2007) Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol4: 629-636.
143. Plesiat P & Nikaido H (1992) Outer membranes of gram-negative bacteria are permeable to steroid probes. Mol Microbiol6: 1323-1333.
144. Poole K (2005) Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Ch49: 479-487.
145. Poole K (2007) Efflux pumps as antimicrobial resistance mechanisms. Ann Med39: 162-176.
146. Pos KM (2009) Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta1794: 782-793.
147. Pugsley AP & Schnaitman CA (1978) Outer membrane proteins of Escherichia coli. VII. Evidence that bacteriophage-directed protein 2 functions as a pore. J Bacteriol133: 1181-1189.
148. Quinn T, O'Mahony R, Baird AW, Drudy D, Whyte P & Fanning S (2006) Multi-drug resistance in Salmonella enterica: efflux mechanisms and their relationships with the development of chromosomal resistance gene clusters. Curr Drug Targets 7: 849-860.
149. Ricci V, Tzakas P, Buckley A & Piddock LJ (2006) Ciprofloxacin-resistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrob Agents Ch50: 38-42.
150. Rice LB (2006) Unmet medical needs in antibacterial therapy. Biochem Pharmacol71: 991-995.
151. Rice LB (2009) The clinical consequences of antimicrobial resistance. Curr Opin Microbiol12: 476-481.
152. Roca I, Espinal P, Martí S & Vila J (2011) First identification and characterization of an AdeABC-like efflux pump in Acinetobacter genomospecies 13TU. Antimicrob Agents Ch55: 1285-1286.
153. Rodríguez-Martínez JM, Poirel L & Nordmann P (2009) Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Ch53: 4783-4788.
154. Ruzin A, Immermann FW & Bradford PA (2010) RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Microb Drug Resist16: 87-89.
155. Schulz R, Vargiu AV, Collu F, Kleinekathöfer U & Ruggerone P (2010) Functional rotation of the transporter AcrB: insights into drug extrusion from simulations. PLoS Comput Biol 6: e1000806.
156. Schumacher A, Steinke P, Bohnert JA, Akova M, Jonas D & Kern WV (2006) Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemoth57: 344-348.
157. Schumacher A, Trittler R, Bohnert JA, Kümmerer K, Pagès JM & Kern WV (2007) Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemoth 59: 1261-1264.
158. Schumacher MA, Miller MC & Brennan RG (2004) Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein. EMBO J23: 2923-2930.
159. Seeger MA, Schiefner A, Eicher T, Verrey F, Diederichs K & Pos KM (2006) Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science313: 1295-1298.
160. Sennhauser G, Amstutz P, Briand C, Storchenegger O & Grutter MG (2007) Drug export pathway of multidrug exporter AcrB revealed by Darpin inhibitors. PLoS Biol5: e7.
161. Sennhauser G, Bukowska MA, Briand C & Grutter MG (2009) Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol389: 134-145.
162. Sigler A, Schubert P, Hillen W & Niederweis M (2000) Permeation of tetracyclines through membranes of liposomes and Escherichia coli. Eur J Biochem267: 527-534.
163. Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev24: 71-109.
164. Smith AM, Govender N & Keddy KH & Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA) (2010) Quinolone-resistant Salmonella Typhi in South Africa, 2003-2007. Epidemiol Infect138: 86-90.
165. Sobel ML, Hocquet D, Cao L, Plésiat P & Poole K (2005) Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Ch49: 1782-1786.
166. Su CC & Yu EW (2007) Ligand-transporter interaction in the AcrB multidrug efflux pump determined by fluorescence polarization assay. FEBS Lett581: 4972-4976.
167. Sugawara E, Nestorovich EM, Bezrukov SM & Nikaido H (2006) Pseudomonas aeruginosa porin OprF exists in two different conformations. J Biol Chem281: 16220-16229.
168. Sugawara E, Nagano K & Nikaido H (2010) Factors affecting the folding of Pseudomonas aeruginosa OprF porin into the one-domain open conformer. mBio1: e00228-e00210.
169. Swick MC, Morgan-Linnell SK, Carlson KM & Zechiedrich L (2011) Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob Agents Ch55: 921-924.
170. Symmons MF, Bokma E, Koronakis E, Hughes C & Koronakis V (2009) The assembled structure of a complete tripartite bacterial multidrug efflux pump. P Natl Acad Sci USA106: 7173-7178.
171. Takatsuka Y & Nikaido H (2009) Covalently linked trimer of the AcrB multidrug efflux pump provides support for the functional rotating mechanism. J Bacteriol191: 1729-1737.
172. Takatsuka Y, Chen C & Nikaido H (2010) Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. P Natl Acad Sci USA107: 6559-6565.
173. Tal N & Schuldiner S (2009) A coordinated network of transporters with overlapping specificities provides a robust survival strategy. P Natl Acad Sci USA106: 9051-9056.
174. Thanassi DG, Suh GS & Nikaido H (1995) Role of outer membrane barrier in efflux-mediated tetracycline resistance of Escherichia coli. J Bacteriol177: 998-1007.
175. Tikhonova EB, Wang Q & Zgurskaya HI (2002) Chimeric analysis of the multicomponent multidrug efflux transporters from gram-negative bacteria. J Bacteriol184: 6499-6507.
176. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM & Woodford N (2010) Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Ch54: 2219-2224.
177. Tornroth-Horsefield S, Gourdon P, Horsefield R, Brive L, Yamamoto N, Mori H, Snijder A & Neutze R (2007) Crystal structure of AcrB in complex with a single transmembrane subunit reveals another twist. Structure15: 1663-1673.
178. Tran QT, Dupont M, Lavigne JP, Chevalier J, Pagès JM, Sotto A & Davin-Regli A (2009) Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases. Antimicrob Agents Ch53: 1652-1656.
179. Trott O & Olson AJ (2010) Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461.
180. Tsuji A, Kubo O, Miyamoto E & Yamana T (1977) Physicochemical properties of β-lactam antibiotics: oil-water distribution. J Pharm Sci 66: 1675-1679.
181. Tumah HN (2009) Bacterial biocide resistance. J Chemotherapy21: 5-15.
182. Vaara M (1992) Agents that increase the permeability of the outer membrane. Microbiol Rev56: 395-411.
183. Vaara M (1993) Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrob Agents Ch37: 2255-2260.
184. Van Bambeke F, Pagès JM & Lee VJ (2010) Inhibitors of bacterial efflux pumps as adjuvants in antibacterial therapy and diagnostic tools for detection of resistance by efflux. Frontiers in Anti-Infective Drug Discovery, Vol. 1, (Atta-ur-Rahman & Choudhary, I., eds) pp. 138-175Bentham EBooks, University of Karachi, Pakistan.
185. Vergidis PI & Falagas ME (2008) Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig D 9: 176-183.
186. Vettoretti L, Floret N, Hocquet D, Dehecq B, Plésiat P, Talon D & Bertrand X (2009a) Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol28: 1217-1222.
187. Vettoretti L, Plésiat P, Muller C, El Garch F, Phan G, Attrée I, Ducruix A & Llanes C (2009b) Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Ch53: 1987-1997.
188. Vila J, Marti S & Sanchez-Cespedes J (2007) Porins, efflux pumps and multidrug resistance in Acinetobacter baumanii. J Antimicrob Chemoth59: 1210-1215.
189. Vu H & Nikaido H (1985) Role of β-lactam hydrolysis in the mechanism of resistance of a β-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum β-lactams. Antimicrob Agents Ch27: 393-398.
190. Wagenlehner FM, Weidner W, Perletti G & Naber KG (2010) Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs15: 375-397.
191. Yan M, Sahin O, Lin J & Zhang Q (2006) Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure. J Antimicrob Chemoth58: 1154-1159.
192. Yao XQ, Kenzaki H, Murakami S & Takada S (2010) Drug export and allosteric coupling in a multidrug transporter revealed by molecular simulations. Nat Commun1: 117.
193. Yasufuku T, Shigemura K, Shirakawa T, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Kinoshita S, Kawabata M & Fujisawa M (2011) Correlation of overexpression of efflux pump genes with antibiotic resistance in Escherichia coli strains clinically isolated from urinary tract infection patients. J Clin Microbiol49: 189-194.
194. Yoshimura F & Nikaido H (1985) Diffusion of β-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Ch27: 84-92.
195. Yoshimura F, Zalman LS & Nikaido H (1983) Purification and properties of Pseudomonas aeruginosa porin. J Biol Chem258: 2308-2314.
196. Yu EW, McDermott G, Zgurskaya HI, Nikaido H & Koshland DE Jr (2003) Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science300: 976-980.
197. Yu EW, Aires JR, McDermott G & Nikaido H (2005) A periplasmic drug-binding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J Bacteriol 187: 6804-6815.
198. Zavascki AP, Carvalhaes CG, Picão RC & Gales AC (2010) Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8: 71-93.
199. Ziha-Zarifi I, Llanes C, Köhler T, Péchère JC & Plésiat P (1999) In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Ch43: 287-291.